Business
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
SAN ANTONIO, Texas, June 24, 2025--China has issued a notification of patent grant to bioAffinity for its novel method of using siRNAs to selectively kill cancer cells.
About this update from Bioaffinity Technologies, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":201,"url":"https://media.zenfs.com/en/business-wire.com/9d1d53cb314df06d7cf5d1f53445c21a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a9oBHDXp4wrOCmAROtRSuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9d1d53cb314df06d7cf5d1f53445c21a","width":480,"height":201}},"lazy":false},{"type":"text","content":"Company research targets topical application for treatment of skin cancers","length":74,"tagName":"p","attribs":{}},{"type":"text","content":"SAN ANTONIO, Texas, June 24, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company’s novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane.","length":470,"tagName":"p"},{"type":"text","content":"The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity’s innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the Company’s new U.S. Patent No. 12,305,171.","length":319,"tagName":"p"},{"type":"text","content":"The invention uses small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro research demonstrates this siRNA-driven double knockdown effectively targets cancer cells from multiple tumor types, including lung, breast, prostate, brain, and skin, without harming normal cells, suggesting a universal mechanism of action.","length":356,"tagName":"p"},{"type":"text","content":"bioAffinity is exploring the application of this technology as a topical treatment specifically designed for cutaneous malignancies and neoplasms of the skin. This development aligns closely with the Company's broader strategy of addressing cancer through both early-stage diagnostics, exemplified by CyPath® Lung, and innovative therapeutic approaches.","length":357,"tagName":"p"},{"type":"text","conten...